Synthesis and biological evaluation of new 13-n-nonylprotoberberine derivatives as antitubercular agents  by Li, Yinghong et al.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2013;3(1):38–452211-3835 & 2013 In
hosting by Elsevier B
http://dx.doi.org/10.1
Corresponding au
E-mail address:
Peer review underwww.elsevier.com/locate/apsb
www.sciencedirect.comORIGINAL ARTICLE
Synthesis and biological evaluation of new
13-n-nonylprotoberberine derivatives as
antitubercular agentsYinghong Li, Yanxin Liu, Yanxiang Wang, Sheng Tang, Danqing SongInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing 100050, China
Received 27 September 2012; revised 15 November 2012; accepted 20 November 2012KEY WORDS
13-n-nonylberberine;
Antitubercular;
Structure–activity rela-
tionship;
MIC;
Drug-resistantstitute of Materia M
.V. All rights rese
016/j.apsb.2012.12
thor. Tel./fax: þ86
songdanqingsdq@h
responsibility of InAbstract Tuberculosis is a serious threat to public health throughout the world. A series of new
13-n-nonylprotoberberine derivatives was designed, synthesized and evaluated for anti-
mycobacterial activity against Mycobacterium tuberculosis strain H37Rv. Several compounds
(2, 11a-c, 11g, 13d, 15c) exhibited excellent anti-tubercular activity with an MIC below 1.0
mg/mL. Notably, compound 13d showed potential antibacterial effect against both drug-susceptible
and multidrug-resistant (MDR) M. tuberculosis with MIC ranges of 0.0625–1.0 mg/mL.
These results suggest a mode of action different from that of the current anti-mycobacterial
drugs rifampicin and isoniazid. Hence, compound 13d is an attractive lead compound for the
development of new antitubercular agents.
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13-n-Nonylprotoberberine derivatives as novel antitubercular agents 391. Introduction
Tuberculosis (TB), which was once considered eradicated, has
again become a major global health concern. Over the past
decade, at least 30 million individuals have died of TB infection
and approximately one-third of the world’s population has been
infected with latent or persistent Mycobacterium tuberculosis
(M. tuberculosis). Moreover, more than 8 million people develop
active TB every year globally, and if the trend continues there will
be a total of 36 million disease-related deaths by the year 20201–3.
The emergence of new multidrug-resistant tuberculosis
(MDR-TB) strains has further complicated the management of
this disease. An outbreak of recently recognized ‘‘extensively
drug-resistant tuberculosis’’ (XDR-TB) threatens global TB
control. A 100% correlation has been observed in XDR-TB
with HIV co-infection and mortality4–7. The difﬁculty in mana-
ging TB is the prolonged treatment duration and the emergence
of drug resistance and co-infection with HIV/AIDS. However,
no new chemical scaffold for the treatment of this disease has
been approved in the past 40 years8–10. There is an urgent need to
discover new classes of molecules that will not be affected by
cross-resistance to current anti-mycobacterial drugs11.
In an attempt to discover novel antitubercular agents, we
recently identiﬁed 13-n-octylprotoberberine (1) as promising and
the corresponding SAR revealed that the n-octyl at the 13-position
signiﬁcantly improved the anti-mycobacterial activity against M.
tuberculosis12. In continuation of our efforts to identify new anti-
TB agents, we turned our attention to chemical modiﬁcations of
the longer linear alkyl side-chains (m48) at the 13-position of
berberine (BBR, Fig. 1). On the basis of this strategy, compounds
2 (13-n-nonyl), 3 (13-n-decyl) and 4 (13-n-undecyl) were synthe-
sized and evaluated for their activity (Fig. 1). The results showed
that compound 2, bearing a n-nonyl at the 13-position, exhibited
the most potent activity against TB among the BBR analogs
possessing different linear alkyl side-chains at the
13-position (m¼0–11). Therefore, in the present study a series
of new 13-nonylprotoberberine analogs was designed, synthesized
and evaluated for their anti-mycobacterial activity against both
drug-susceptible and drug-resistantM. tuberculosis strains isolated
from the patients with tuberculosis infections.2. Results and discussion
2.1. Synthetic routes
Twenty target compounds were synthesized using BBR,
5 or 613 as the starting materials as described in Scheme 1.Figure 1 The chemical structures and anti-mycobacterial activities o
MIC: 0.848 mg/mL; 3: m¼10, MIC: 4.0 mg/mL; 4: m¼11, MIC: 1.0 mThese compounds were selectively reduced to the correspond-
ing dihydroprotoberberines 7a–c with NaBH4 in the presence
of K2CO3/NaOH
14. Intermediates 7a–c were then mixed with
various aldehydes in an ethanol/acetic acid (8/2) mixture at
8595 1C for 5 h, followed by acidiﬁcation with HCl (2 M) to
provide 13-alkylprotoberberine analogs 2–4 and 8–9 (Route
A) in total yields of 1536%14,15.
In Route B, intermediate 10 was prepared by a decomposi-
tion reaction of compound 2 at 195210 1C under vacuum
(3040 mm Hg) for 30 min followed by recrystallization in
ethanol/concentrated HCl (95/5, v/v) in an 89% yield16. Final
products 11a–f were obtained by an esteriﬁcation reaction of
10 with acyl chloride using pyridine as the base in acetonitrile
at reﬂux temperature in yields of 2548%17,18, while 11g was
obtained through an alkylation reaction of 10 with alkyl
halide using K2CO3/KOH as the base in DMF at 6080 1C,
with yields of 26%19,20.
Compound 2 was treated with phloroglucinol in H2SO4
(60%) at 9095 1C to afford the key intermediate 12 in an
82% yield21, which was then put through an alkylation
reaction with an alkyl halide to afford target compounds
13a–d in total yields of 524%19,20 (Route C). Target
compounds 15a–c were obtained by mixing compound 2 with
AlCl3 in CH2Cl2 to afford intermediate 14
22–24 followed by an
alkylation reaction with alkyl halide in total yields of 23–
32%19,20 (Route D). All desired products were puriﬁed by
ﬂash chromatography using CH2Cl2/CH3OH as the gradient
eluent.2.2. SAR analysis for anti-mycobacterial activity
All the synthesized derivatives were ﬁrst evaluated for their
activity against the multiplication of wild-type M. tuberculosis
strain H37Rv by the microplate alamar blue assay (MABA).
Rifampicin (RIF) and isoniazid (INH) were used as reference
drugs. The structures of 20 new 13-n-nonylprotoberberine
derivatives and their anti-mycobacterial activities against M.
tuberculosis H37Rv are shown in Table 1.
We ﬁrst concentrated SAR analysis on the variation of the
substituents on the D ring. When the methoxy group was
transferred from the 9-position to the 11-position, the resul-
tant 8 showed decreased anti-mycobacterial activity with an
MIC of 2.0 mg/mL as compared to compound 2. Replacement
of the 9-methoxy with a hydrogen, hydroxyl, acetyloxy,
propionyloxy, butyryloxy, hexanoyloxy, octanoyloxy, decan-
oyloxy or propoxy, generated nine new compounds (9, 10,
11a–g) for testing. The results showed that compounds 11a–bf compounds BBR and 1–4 (1: m¼8, MIC: 2.0 mg/mL; 2: m¼9,
g/mL).
Scheme 1 Synthesis of the 13-substituted protoberberine derivatives.Reagents and conditions for the chemical synthesis: (a) NaBH4,
CH3OH; (b) RCHO, acetic acid, ethanol (80%); (c) 195210 1C, 3040 mm Hg, 2040 min; (d) phloroglucinol, 60% H2SO4, 9095 1C,
1015 min; (e) AlCl3, CH2Cl2, 3 days, r.t.; (f) RCOX, pyridine, CH3CN, reﬂux. (g) RX, K2CO3/KOH, DMF, 6080 1C.
Yinghong Li et al.40and 11g exhibited a remarkable MIC of 0.125 mg/mL against
M. tubercolusis H37Rv, much greater than that of the lead
compound 2. The results indicated that introduction of a
suitable substituent at the 9-position, such as acetyloxy,
propionyloxy or propoxy, might be helpful for the anti-
mycobacterial activity.
Next, SAR was carried out to explore at the 2- and 3-
positions on the A ring. When the oxacyclopentene was
opened, the resultant compound 12 showed potent activity
against TB at an MIC of 0.5 mg/mL, slightly higher than that
of its parent 2. Introducing a methoxy, ethoxy or ethylene-
dioxy at 2- and/or 3-position (13a–d) displayed similar
activities with MIC values between 0.25 and 0.5 mg/mL. In
another variation, further modiﬁcations were carried out at
the 2-, 3- and 9-positions. The substituents, including a
hydroxyl, ethoxyl or ethylenedioxy, were introduced to some
or all of these positions. Among the four new analogs (14,
15a–c), compound 15c, possessing 2,3,9-triethoxy exhibited
the strongest anti-tubercular activity with an MIC of
0.0625 mg/mL. We deduced that introduction of a side-chain
at the 2- and/or 3-position(s), especially ethoxy, mightsigniﬁcantly enhance the anti-mycobacterial activity against
M. tuberculosis.2.3. Anti-resistant TB effect of the key compounds
Among the newly synthesized compounds, most of them
exhibited promising activities against the wild-type strain
H37Rv with MIC ranges of 0.06252.0 mg/mL. Although
compound 15c afforded the most potent effect against
M. tuberculosis, it showed a metabolic instability in vivo (data
not shown). We consider that di-ethoxy at the 2- and
3-positions might form a blockage that reduces the stability
of compound 15c, and subsequently be metabolized easily
in vivo. Therefore, compounds 2, 11a, 11c and 13d possessing
various substituents at 2-, 3-, and 9-positions were selected for
evaluation of their anti-mycobacterial activity against MDR
strains of M. tuberculosis. As described in Table 2, RIF and
INH showed a partial decrease or complete loss in activity
against MDR stains 44, 83, 164, 431 and 926, isolated from
patients with tuberculosis in China. Compounds 11a and 11c
Table 1 SAR of the target compounds against
M. tuberculosis strain H37Rv.
a
R2
R1
N
+
R3
OCH3
C9H19
R4
Cl
-
Compd. R1 R2 R3 R4 MIC
b
(mg/mL)
2 OCH2O OCH3 H 0.848
8 OCH2O H OCH3 2.0
9 OCH2O H H 4.0
10 OCH2O OH H 2.0
11a OCH2O CH3CO2 H 0.125
11b OCH2O C2H5CO2 H 0.125
11c OCH2O n-C3H7CO2 H 0.25
11d OCH2O n-C5H11CO2 H 2.0
11e OCH2O n-C7H15CO2 H 2.0
11f OCH2O n-C8H17CO2 H 2.0
11g OCH2O n-C3H7O H 0.125
12 OH OH OCH3 H 0.5
13a OH OC2H5 OCH3 H 0.5
13b OCH3 OCH3 OCH3 H 0.5
13c OC2H5 OC2H5 OCH3 H 0.5
13d OCH2CH2O OCH3 H 0.25
14 OH OH OH H 16
15a OCH2CH2O OH H 2.0
15b OH OC2H5 OC2H5 H 0.5
15c OC2H5 OC2H5 OC2H5 H 0.0625
INHc 0.0625
RIFd 0.0625
aStrain H37Rv was isolated from patients with tuberculosis
in China.
bMIC: minimum inhibitory concentration.
cINH: Isonizazid.
dRIF: Rifampin.
Table 2 Antitubercular activity of the key compounds
against MDR-TB strainsa (MICb: mg/mL).
Compd. 44 83 164 431 926 H37Rv
2 2 2 4 ND 4 0.848
11a 2 4 2 ND 2 0.125
11c 4 4 8 ND 2 0.25
13d 0.0625 0.0625 0.5 0.5 ND 0.25
INHc 432 432 432 464 432 0.0625
RIFd 8 4 8 64 8 0.0625
aMDR strains were isolated from patients with tuberculosis
in China.
bMIC: minimum inhibitory concentration.
cINH: Isoniazid.
dRIF: Rifampin.
13-n-Nonylprotoberberine derivatives as novel antitubercular agents 41showed the moderate inhibition activities, while compound
13d displayed the most potent anti-mycobacterial effect with
MIC values of 0.0625–0.5 mg/mL, suggesting a different mode
of action from RIF and INH. The results revealed that
compound 13d represents an attractive lead compound for
the development of new anti-TB agents.3. Conclusions
In conclusion, a novel class of 13-n-nonylberberine derivatives
with promising antitubercular activity was identiﬁed. SAR
analysis revealed that a 13-n-nonyl side-chain might play
an important role in anti-mycobacterial activities against
M. tuberculosis strains. Among these analogs, the newly
synthesized compound 13d exhibited an excellent effect
toward both drug-susceptible and drug-resistant strains of
M. tuberculosis, indicating a different mode of action from themarketed anti-mycobacterial drugs RIF and INH. Elucidation
of the mode of action of 13d is one of the goals of the ongoing
research program in our laboratories.4. Experimental
4.1. Chemistry
Melting point (mp) was obtained with CXM-300 melting point
apparatus and uncorrected. The 1H NMR spectra was
performed on a Varian Inova 400 MHz spectrometer (Varian,
San Francisco, CA) and 13C NMR on a Bruker Avance III
400 spectrometer in CD3OD or (CD3)2SO, with Me4Si as the
internal standard. ESI high-resolution mass spectra (HRMS)
were recorded on an Autospec UItima-TOF mass spectro-
meter (Micromass UK Ltd, Manchester, UK). Flash chroma-
tography was performed on CombiﬂashRf 200 (Teledyne,
Nebraska, USA), particle size 0.038 mm.
4.2. General procedure for the synthesis of compounds 2–4 and
8–9 (Procedure A)
4.2.1. 2,3-Methylenedioxy-9,10-dimethoxy-13-n-
nonylprotoberberine chloride (2)
To a stirred solution of BBR (7.43 g, 20 mmol) and K2CO3
(8.30 g, 60 mmol) in methanol (250 mL), 5% NaOH (10 mL)
solution containing NaBH4 (0.80 g, 21 mmol) was added
dropwise. The reaction mixture was stirred at room tempera-
ture for 2 h and the precipitated product was ﬁltered, washed
with water (20 mL) and 30% ethanol (20 mL), and then
recrystallized from absolute ethanol to provide 7a as a dark
green solid.
To a stirred solution of 7a (7.0 g, 20.2 mmol) in 80%
ethanol (200 mL), nonylaldehyde (10 mL) and acetic acid
(50 mL) were added. The reaction mixture was heated at
8595 1C for 5 h. The crude reaction was then concentrated,
and the red oily residue was suspended in diethyl ether
(200 mL) and stirred at room temperature for 2 h. After
ﬁltration, the diethyl ether layer was collected and concen-
trated, and the residue was acidiﬁed by 2% HCl (100 mL), and
stirred at room temperature for 0.5 h. The solid was obtained
by ﬁltration to afford the title compound 2 (3.57 g, 36%) as a
yellow powder. Mp 162164 1C; 1H NMR (CD3OD): d 0.84
Yinghong Li et al.42(t, J¼6.8 Hz, 3H), 1.041.35 (m, 12H), 1.74 (br, 2H), 3.07 (t,
J¼5.6 Hz, 2H), 3.82 (t, J¼5.2 Hz, 2H), 4.09 (s, 6H), 4.79 (s,
2H), 6.17 (s, 2H), 7.17 (s, 1H), 7.28 (s, 1H), 8.19 (s, 2H),
9.89 ppm (s, 1H); 13C NMR [(CD3)2SO] d 13.9, 22.1, 27.3,
28.4, 28.6 (2), 28.9, 30.4, 31.2 (2), 57.0 (2), 62.0, 102.1, 108.3,
109.1, 120.2, 121.2, 121.4, 125.9, 132.2, 134.0, 134.2, 135.8,
144.2, 144.3, 146.5, 149.0, 150.2 ppm; HR MS-ESI: m/z
[M–Cl]þ calcd. for C29H36NO4Cl: 462.2644, Found: 462.2654.
4.2.2. 2,3-Methylenedioxy-9,10-dimethoxy-13-n-
monodecylprotoberberine chloride (3)
This compound (3) was obtained from capraldehyde and 7a as
a yellow powder (2.58 g, 25%) using the procedure A. Mp
106108 1C; 1H NMR (CD3OD) d 0.85 (t, J¼6.8 Hz, 3H),
1.221.34 (m, 12H), 1.35 (br, 2H), 1.73 (br, 2H), 3.07 (t,
J¼5.6 Hz, 2H), 3.81 (br, 2H), 4.08 (s, 6H), 4.78 (s, 2H), 6.17
(s, 2H), 7.15 (s, 1H), 7.28 (s, 1H), 8.20 (s, 2H), 9.89 ppm (s,
1H); 13C NMR [(CD3)2SO] d 13.9, 22.0, 27.3, 28.4, 28.5, 28.6,
28.2, 28.9, 30.4, 31.2 (2), 57.0 (2), 62.0, 102.1, 108.3, 109.1,
120.2, 121.2, 121.4, 125.9, 132.2, 134.0, 134.1, 135.7, 144.2,
144.3, 146.5, 149.0, 150.2 ppm; HR MS-ESI: m/z [MCl]þ
calcd. for C30H38NO4Cl: 476.2801, Found: 476.2776.
4.2.3. 2,3-Methylenedioxy-9,10-dimethoxy-13-n-
undecylprotoberberine chloride (4)
This compound (4) was obtained from undecylic aldehyde and
7a as a yellow powder (2.30 g, 24%) using procedure A. Mp
101103 1C; 1H NMR (CD3OD) d 0.84 (t, J¼6.8 Hz, 3H),
1.101.29 (m, 14H), 1.41 (br, 2H), 1.80 (br, 2H), 3.06 (t,
J¼5.6 Hz, 2H), 3.37 (t, J¼8.0 Hz, 2H), 4.07 (s, 3H), 4.15 (s,
3H), 4.73 (t, J¼5.6 Hz, 2H), 6.07 (s, 2H), 6.98 (s, 1H), 7.24 (s,
1H), 8.10 (d, J¼9.2 Hz, 2H), 9.72 ppm (s, 1H); 13C NMR
[(CD3)2SO] d 13.9, 22.1, 27.3, 28.4, 28.6, 28.7, 28.8, 28.9 (2),
30.4, 31.2 (2), 56.9, 57.0, 62.0, 102.1, 108.3, 109.1, 120.3, 121.2,
121.4, 125.9, 132.2, 134.0, 134.1, 135.7, 144.3, 144.4, 146.5,
149.0, 150.2 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C31H40NO4Cl: 490.2957, Found: 490.2964.
4.2.4. 2,3-Methylenedioxy-10,11-dimethoxy-13-n-
nonylprotoberberine chloride (8)
Intermediate 7b was obtained from reduction of compound
513 following the same procedure of 7a, and 8 was obtained
from nonylaldehyde and intermediate 7b as a yellow powder
(220 mg, 16%) using procedure A. Mp 109110 1C; 1H NMR
(CD3OD) d 0.84 (t, J¼7.2 Hz, 3H), 1.161.37 (m, 12H), 1.77
(br, 2H), 3.06 (t, J¼5.6 Hz, 2H), 3.34 (t, J¼7.2 Hz, 2H), 3.99
(s, 3H), 4.12 (s, 3H), 4.65 (s, 2H), 6.17 (s, 2H), 7.17 (s, 1H),
7.27 (s, 1H), 7.54 (s, 1H), 7.80 (s, 1H), 9.70 ppm (s, 1H);
13C NMR [(CD3)2SO] d 13.9, 22.1, 27.5, 28.3, 28.5, 28.6, 28.8,
28.9, 29.3, 31.2, 56.2, 56.4, 56.7, 102.1, 103.6, 107.7, 108.4,
109.1, 120.5, 121.7, 132.1, 133.9, 135.6, 136.7, 144.8, 146.5,
149.0, 151.8, 157.2 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C29H36NO4Cl: 462.2644, Found: 462.2636.
4.2.5. 2,3-Methylenedioxy-10-methoxy-13-n-
nonylprotoberberine chloride (9)
Intermediate 7c was obtained from reduction of compound 613
following the same procedure of 7a, and 9 was obtained from
nonylaldehyde and intermediate 7c as a yellow powder (10 mg,
15%) using procedure A. Mp 9596 1C; 1H NMR (CD3OD) d
0.84 (t, J¼6.8 Hz, 3H), 1.211.35 (m, 12H), 1.73 (br, 2H),3.09 (t, J¼5.6 Hz, 2H), 3.34 (br, 2H), 4.00 (s, 3H), 4.72 (t,
J¼5.6 Hz, 2H), 6.18 (s, 2H), 7.17 (s, 1H), 7.30 (s, 1H), 7.81 (s,
1H), 7.87, 8.38 (dd, J¼9.2 Hz, 2H), 9.86 ppm (s, 1H);
13C NMR [(CD3)2SO] d 13.9, 22.1, 27.3, 28.4, 28.5, 28.6,
28.8, 28.9, 30.4, 31.2, 56.2, 57.0, 102.1, 107.7, 108.4, 109.1,
120.3, 127.0, 127.2, 129.0, 133.5, 133.9, 134.5, 136.5, 146.6,
147.0, 149.0, 159.7 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C28H34NO3Cl: 432.2539, Found: 432.2534.
4.3. General procedure for the synthesis of compounds 10,
11a–f (Procedure B)
4.3.1. 2,3-Methylenedioxy-9-hydroxy-10-methoxy-13-n-
nonylprotoberberine chloride (10)
Compound 2 (1.58 g, 3.16 mmol) was heated at 195210 1C
for 1015 min under vacuum (3040 mmHg) to afford a
black oil, which was acidiﬁed with ethanol/concentrated HCl
(95/5). The solvent was removed by evaporation, the residue
was collected and then puriﬁed by ﬂash chromatography over
silica gel using CH2Cl2/CH3OH as the gradient eluent,
affording compound 10 (1.36 g, 89%) as a dark red powder.
Mp 104106 1C; 1H NMR (CD3OD) d 0.85 (t, J¼6.8 Hz,
3H), 1.221.35 (m, 12H), 1.75 (br, 2H), 3.05 (t, J¼5.6 Hz,
2H), 3.29 (t, J¼8.0 Hz, 2H), 4.04 (s, 3H), 4.74 (s, 2H), 6.17 (s,
2H), 7.13(s, 1H), 7.27 (s, 1H), 7.86, 8.07 (dd, J¼9.2 Hz, 2H),
9.90 ppm (s, 1H); 13C NMR [(CD3)2SO] d 13.9, 22.1, 27.5,
28.4, 28.6 (2), 28.9, 30.1, 31.2 (2), 56.7, 56.9, 102.0, 108.3,
109.1, 115.9, 117.2, 120.5, 124.6, 131.6, 133.6, 133.9, 134.8,
144.4, 144.6, 145.3, 146.5, 148.8 ppm; HR MS-ESI: m/z
[MCl]þ calcd. for C28H34NO4Cl: 448.2485, Found: 448.2491.
4.3.2. 2,3-Methylenedioxy-9-acetyloxy-10-methoxy-13-n-
nonylprotoberberine chloride (11a)
To a solution of CH3CN (5 mL) was added 10 (200 mg,
0.41 mmol) at room temperature and heated to form a dark-
red solution, to which was then added anhydrous pyridine
(0.036 mL) and acetyl chloride (0.143 mL, 2.0 mmol). The
resulting mixture was reﬂuxed at 7580 1C for 68 h. The
solvent was removed by evaporation, the crude product was
puriﬁed by ﬂash chromatography over silica gel using CH2Cl2/
CH3OH (95/5) as the gradient eluent, affording compound 11a
(82 mg, 38%) as a yellow powder. Mp 98100 1C; 1H NMR
(CD3OD) d 0.85 (t, J¼6.8 Hz, 3H), 1.221.26(m, 10H),
1.351.37 (m, 2H), 1.75 (br, 2H), 2.51 (s, 3H), 3.09 (t,
J¼5.6 Hz, 2H), 3.38 (t, J¼8.4 Hz, 2H), 4.05 (s, 3H), 4.79 (s,
2H), 6.17 (s, 2H), 7.16 (s, 1H), 7.30 (s, 1H), 8.25, 8.42 (dd,
J¼9.6 Hz, 2H), 9.93 ppm (s, 1H); 13C NMR [(CD3)2SO] d
13.9, 20.7, 21.1, 22.1, 27.2, 28.4, 28.6, 28.9, 30.2, 30.5, 31.2,
57.0, 57.2, 102.1, 108.3, 109.2, 120.2, 121.0, 124.6, 125.0, 132.1,
134.1, 134.2, 134.7, 136.4, 143.3, 146.6, 149.1, 150.2,
168.0 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C30H36NO5Cl: 490.2594, Found: 490.2587.
4.3.3. 2,3-Methylenedioxy-9-n-propionyloxy-10-methoxy-13-
n-nonylprotoberberine chloride (11b)
This compound (11b) was obtained from propionyl chloride
and compound 10 as a yellow powder (106 mg, 48%) using
procedure B. Mp 106108 1C; 1H NMR (CD3OD) d 0.86 (t,
J¼7.2 Hz, 3H), 1.161.27 (m, 13H), 1.361.38 (m, 2H), 1.76
(br, 2H), 2.89 (br, 2H), 3.10 (t, J¼5.6 Hz, 2H), 3.39 (t,
J¼8.0 Hz, 2H), 4.06 (s, 3H), 4.80 (s, 2H), 6.19 (s, 2H), 7.17
13-n-Nonylprotoberberine derivatives as novel antitubercular agents 43(s, 1H), 7.32 (s, 1H), 8.26, 8.43 (dd, J¼9.6 Hz, 2H), 9.90 ppm
(s, 1H); 13C NMR [(CD3)2SO] d 8.7, 9.0, 13.9, 22.0, 26.6, 26.8,
27.2, 28.4, 28.5, 28.8, 30.5, 31.1, 57.0, 57.2, 102.1, 108.3, 109.1,
120.1, 120.9, 124.5, 125.0, 132.0, 134.1, 134.2, 134.6, 136.4,
143.3, 146.5, 149.1, 150.1, 171.4 ppm; HR MS-ESI: m/z
[MCl]þ calcd. for C31H38NO5Cl: 504.2750, Found: 504.2708.
4.3.4. 2,3-Methylenedioxy-9-n-butyryloxy-10-methoxy-13-n-
nonylprotoberberine chloride (11c)
This compound (11c) was obtained from butyryl chloride and
compound 10 as a yellow powder (97 mg, 42%) using
procedure B. Mp 8587 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼6.8 Hz, 3H), 1.05 (t, J¼7.2 Hz, 3H), 1.221.26 (m, 10H),
1.351.37 (m, 2H), 1.731.79 (m, 4H), 2.83 (t, J¼7.2 Hz,
2H), 3.09 (t, J¼5.6 Hz, 2H), 3.38 (t, J¼8.4 Hz, 2H), 4.04 (s,
3H), 4.78 (s, 2H), 6.18 (s, 2H), 7.16 (s, 1H), 7.30 (s, 1H), 8.25,
8.42 (dd, J¼9.6 Hz, 2H), 9.87 ppm (s, 1H); 13C NMR
[(CD3)2SO] d 13.3, 13.9, 17.7, 17.8, 22.0, 27.2, 28.4, 28.6,
28.8, 30.5, 31.1, 35.0, 35.5, 57.0, 57.1, 102.1, 108.3, 109.1,
120.1, 120.9, 124.5, 125.0, 132.1, 134.1, 134.2, 134.6, 136.4,
143.3, 146.5, 149.1, 150.1, 170.5 ppm; HR MS-ESI: m/z
[MCl]þ calcd. for C32H40NO5Cl: 518.2907, Found: 518.2870.
4.3.5. 2,3-Methylenedioxy-9-n-hexanoyloxy-10-methoxy-13-
n-nonylprotoberberine chloride (11d)
This compound (11d) was obtained from caproyl chloride and
compound 10 as a yellow powder (61 mg, 25%) using
procedure B. Mp 8284 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼7.2 Hz, 3H), 0.92 (t, J¼7.2 Hz, 3H), 1.221.26 (m, 10H),
1.351.45 (m, 6H), 1.701.76 (m, 4H), 2.84 (t, J¼7.2 Hz,
2H), 3.09 (t, J¼5.6 Hz, 2H), 3.38 (t, J¼8.4 Hz, 2H), 4.04 (s,
3H), 4.78 (s, 2H), 6.18 (s, 2H), 7.16 (s, 1H), 7.30 (s, 1H), 8.25,
8.42 (dd, J¼9.6 Hz, 2H), 9.85 ppm (s, 1H); 13C NMR
[(CD3)2SO] d 13.9 (2), 21.8, 22.1, 23.9, 27.2, 28.4 (2), 28.6
(2), 28.9, 30.5 (2), 31.2, 33.2, 57.0, 57.1, 102.1, 108.3, 109.2,
120.2, 121.0, 124.5, 125.0, 132.1, 134.1, 134.2, 134.7, 136.4,
143.3, 146.6, 149.1, 150.1, 170.7 ppm; HR MS-ESI: m/z
[MCl]þ calcd. for C34H44NO5Cl: 546.3218, Found: 546.3226.
4.3.6. 2,3-Methylenedioxy-9-n-octanoyloxy-10-methoxy-13-n-
nonylprotoberberine chloride (11e)
This compound (11e) was obtained from octanoyl chloride
and compound 10 as a yellow powder (114 mg, 45%) using
procedure B. Mp 76–78 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼7.2 Hz, 3H), 0.88 (t, J¼7.2 Hz, 3H), 1.221.46 (m, 20H),
1.711.77 (m, 4H), 2.84 (t, J¼7.2 Hz, 2H), 3.09 (t, J¼5.6 Hz,
2H), 3.38 (t, J¼8.0 Hz, 2H), 4.04 (s, 3H), 4.78 (s, 2H), 6.18 (s,
2H), 7.16 (s, 1H), 7.30 (s, 1H), 8.25, 8.42 (dd, J¼9.6 Hz, 2H),
9.86 ppm (s, 1H); 13C NMR [(CD3)2SO] d 22.0 (2), 24.2, 24.5,
27.2, 28.3, 28.4, 28.5, 28.6 (2), 28.9, 30.5, 31.1, 31.2 (2),
33.2, 33.6, 57.0, 57.1, 102.1, 108.3, 109.2, 120.2, 121.0,
124.5, 125.0, 132.1, 134.1, 134.2, 134.7, 136.4, 143.3, 146.5,
149.1, 150.1, 170.6 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C36H48NO5Cl: 574.3530, Found: 574.3538.
4.3.7. 2,3-Methylenedioxy-9-n-decanoyloxy-10-methoxy-13-
n-nonylprotoberberine chloride (11f)
This compound (11f) was obtained from pelargonyl chloride
and compound 10 as a yellow powder (34 mg, 14%) using
procedure B. Mp 7677 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼7.2 Hz, 3H), 0.87 (t, J¼7.2 Hz, 3H), 1.221.44 (m, 22H),1.711.77 (m, 4H), 2.84 (t, J¼7.2 Hz, 2H), 3.09 (t, J¼5.6 Hz,
2H), 3.36 (t, J¼8.0 Hz, 2H), 4.04 (s, 3H), 4.78 (s, 2H), 6.18 (s,
2H), 7.16 (s, 1H), 7.30 (s, 1H), 8.25, 8.42 (dd, J¼9.6 Hz, 2H),
9.86 ppm (s, 1H); 13C NMR [(CD3)2SO] d 13.9 (2), 22.1 (2),
24.2, 27.2, 28.3, 28.4, 28.6 (3), 28.7, 28.9, 30.5, 31.2 (3),
33.2, 57.0, 57.1, 102.1, 108.3, 109.2, 120.2, 121.0, 124.6,
125.0, 132.1, 134.1, 134.2, 134.7, 136.4, 143.3, 146.6, 149.1,
150.1, 170.6 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C37H50NO5Cl: 588.3689, Found: 588.3664.4.3.8. 2,3-Methylenedioxy-9-n-propoxy-10-methoxy-13-n-
nonylprotoberberine chloride (11g)
To a stirred solution of 10 (117 mg, 0.24 mmol) and KOH
(54.0 mg, 0.96 mmol) in DMF (10 mL), propyl iodide
(0.097 mL, 1.00 mmol) was added. The reaction mixture was
stirred at 70 1C for 56 h. The solvent was removed by
evaporation, the residue was acidiﬁed by 2 M HCl, the solid
was collected by ﬁltration and then puriﬁed by ﬂash chroma-
tography over silica gel using CH2Cl2/CH3OH (95/5) as the
gradient eluent, affording compound 11g (33 mg, 26%) as a
brown powder. Mp 108110 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼6.8 Hz, 3H), 1.04 (t, J¼7.6 Hz, 3H), 1.221.26 (m, 10H),
1.341.36 (m, 2H), 1.74 (br, 2H), 1.841.91 (m, 2H), 3.07 (t,
J¼5.6 Hz, 2H), 3.33 (t, J¼8.0 Hz, 2H), 4.08 (s, 3H), 4.24 (t,
J¼6.8 Hz, 2H), 4.80 (s, 2H), 6.17 (s, 2H), 7.16 (s, 1H), 7.28 (s,
1H), 8.18 (s, 2H), 9.75 ppm (s, 1H); 13C NMR [(CD3)2SO] d
10.2, 13.9, 22.0, 22.8, 27.3, 28.4, 28.6 (2), 28.9, 30.3, 31.2 (2),
57.0, 57.1, 75.9, 102.1, 108.3, 109.1, 120.3, 121.2, 121.4, 125.8,
132.2, 134.0, 134.2, 135.7, 143.4, 144.1, 146.5, 149.0,
150.2 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C31H40NO4Cl: 490.2955, Found: 490.2963.4.4. General procedure for the synthesis of compounds 12,
13ad (Procedure C)
4.4.1. 2,3-Dihydroxy-9,10-dimethoxy-13-n-
nonylprotoberberine chloride (12)
To a stirred solution of 60% H2SO4 (60 mL), phloroglucin
(1.69 g, 10.39 mmol) was added portion-wise to form a
colorless solution, after which compound 2 (1.50 g,
3.01 mmol) was added portion-wise and the mixture was
stirred at 9095 1C for 1015 min. The mixture was then
poured into saturated brine (30 mL) immediately with rapid
stirring, and the resulting mixture was stirred at room
temperature for 2 h and cooled allowing precipitation. After
ﬁltration and a water wash the ﬁlter cake layer was adjusted to
neutral with NaOH (1 M), then adjusted to acidity with HCl
(2 M), stirred, ﬁltered to collect the precipitate, followed by
recrystallization with ethanol/concentrated HCl (95/5) to
afford compound 12 (1.2 g, 82%) as a dark red powder. Mp
118120 1C; 1H NMR (CD3OD) d 0.85 (t, J¼6.8 Hz, 3H),
1.241.31 (m, 10H), 1.421.46 (m, 2H), 1.801.83 (m, 2H),
2.98 (t, J¼5.6 Hz, 2H), 3.37 (t, J¼8.0 Hz, 2H), 4.06 (s, 3H),
4.14 (s, 3H), 4.70 (t, J¼5.6 Hz, 2H), 6.83 (s, 1H), 7.22 (s, 1H),
8.07 (s, 2H), 9.66 ppm (s, 1H); 13C NMR [(CD3)2SO] d 13.8,
22.0, 26.6, 28.4, 28.6, 28.7, 28.8, 28.9, 30.4, 31.2, 56.9, 57.3,
61.9, 114.6, 116.5, 117.6, 120.9, 121.0, 125.8, 130.2, 132.3,
133.1, 136.4, 144.0 (2), 144.1, 147.9, 149.7 ppm; HR MS-ESI:
m/z [MCl]þ calcd. for C28H36NO4Cl: 450.2644, Found:
450.2671.
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To a stirred solution of 12 (234 mg, 0.43 mmol) and K2CO3
(138 mg, 1.00 mmol) in DMF (10 mL), ethyl bromide
(35.9 mL, 0.48 mmol) was added. The reaction mixture was
stirred at 70 1C for 56 h. The solvent was removed by
evaporation, and the residue was acidiﬁed by 2 M HCl. The
precipitate was collected by ﬁltration and then puriﬁed by
ﬂash chromatography over silica gel using CH2Cl2/CH3OH
(95/5) as the gradient eluent, affording compound 13a (12 mg,
5%) as a brown powder. Mp 8082 1C; 1H NMR (CD3OD) d
0.85 (t, J¼7.2 Hz, 3H), 1.231.28 (m, 12H), 1.39 (t, J¼7.2
Hz, 3H), 1.77 (br, 2H), 3.03 (t, J¼5.2 Hz, 2H), 3.37 (t,
J¼8.0 Hz, 2H), 4.08 (s, 6H), 4.124.17 (m, 2H), 4.78 (s,
2H), 7.08 (s, 1H), 7.23 (s, 1H), 8.17 (s, 2H), 9.35 (s, 1H),
9.85 ppm (s, 1H); 13C NMR [(CD3)2SO] d 13.9, 14.6, 22.0,
24.8, 26.9, 28.6 (2), 28.8, 29.0, 30.5, 31.2, 56.9, 57.3, 61.9, 63.9,
112.0, 116.1, 116.6, 119.0, 121.1, 123.1, 125.8, 130.1, 132.3,
133.6, 136.1, 144.2, 145.3, 148.4, 149.9 ppm; HR MS-ESI: m/z
[MCl]þ calcd. for C30H40NO4Cl: 478.2962, Found: 478.2952.
4.4.3. 2,3,9,10-Tetramethoxy-13-n-nonylprotoberberine
chloride (13b)
This compound (13b) was obtained from methyl iodide and
compound 12 as a brown powder (81 mg, 26%) using
Procedure C. Mp 120122 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼7.2 Hz, 3H), 1.221.26 (m, 10H), 1.431.45 (m, 2H), 1.81
(br, 2H), 3.10 (t, J¼5.6 Hz, 2H), 3.36 (t, J¼8.4 Hz, 2H), 3.85
(s, 3H), 3.88 (s, 3H), 4.09 (s, 6H), 4.80 (s, 2H), 7.18 (s, 1H),
7.31 (s, 1H), 8.19 (s, 2H), 9.88 ppm (s, 1H); 13C NMR
[(CD3)2SO] d 13.9, 22.1, 26.9, 28.6, 28.7, 28.9, 29.1, 29.3,
30.9, 31.2, 55.7, 55.8, 57.0, 57.2, 62.0, 111.2, 112.8, 119.0,
121.1, 121.2, 126.0, 132.2, 132.3, 133.7, 135.9, 144.2, 144.4,
147.3, 150.0, 150.7 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C30H40NO4Cl: 478.2955, Found: 478.2957.
4.4.4. 2,3-Diethoxy-9,10-dimethoxy-13-n-nonylprotoberberine
chloride (13c)
This compound (13c) was obtained from ethyl bromide and
compound 12 as a brown powder (80 mg, 24%) using
Procedure C. Mp 7374 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼7.2 Hz, 3H), 1.231.45 (m, 20H), 1.80 (br, 2H), 3.08 (t,
J¼5.2 Hz, 2H), 4.08 (s, 6H), 4.134.19 (m, 4H), 4.80 (s, 2H),
7.16 (s, 1H), 7.29 (s, 1H), 8.18 (s, 2H), 9.88 ppm (s, 1H); 13C
NMR [(CD3)2SO] d 13.8, 14.5, 14.7, 22.0, 26.8, 28.6, 28.7,
28.9, 29.0, 29.2, 30.8, 31.1, 56.9, 57.1, 61.9, 63.9, 64.3, 112.1,
114.5, 118.8, 121.0, 121.1, 125.9, 132.2, 132.3, 133.5, 135.8,
144.1, 144.3, 146.4, 149.9, 150.2 ppm; HR MS-ESI: m/z
[MCl]þ calcd. for C32H44NO4Cl: 506.3270, Found: 506.3269.
4.4.5. 2,3-Ethylenedioxy-9,10-dimethoxy-13-n-
nonylprotoberberine chloride (13d)
This compound (13d) was obtained from 1,2-dibromoethane
and compound 12 as a brown powder (69 mg, 22%) using
Procedure C. Mp 104105 1C; 1H NMR (CD3OD) d 0.86 (t,
J¼7.2 Hz, 3H), 1.251.30 (m, 10H), 1.431.47 (m, 2H), 1.79
(br, 2H), 3.05 (t, J¼5.6 Hz, 2H), 3.29 (t, J¼8.4 Hz, 2H), 4.08
(s, 6H), 4.314.37 (m, 4H), 4.80 (s, 2H), 7.05 (s, 1H), 7.24 (s,
1H), 8.19 (s, 2H), 9.88 ppm (s, 1H); 13C NMR [(CD3)2SO] d
13.9, 22.1, 26.7, 28.4, 28.6 (2), 28.9, 30.4, 31.2 (2), 57.0, 57.3,
62.0, 64.1, 64.6, 116.2, 118.0, 119.8, 121.2, 121.4, 125.9, 132.0,132.1, 134.1, 135.4, 142.1, 144.2, 144.5, 145.3, 150.2 ppm; HR
MS-ESI: m/z [MCl]þ calcd. for C30H38NO4Cl: 476.2799,
Found: 476.2804.
4.5. General procedure for the synthesis of compounds 14,
15a-c (Procedure D)
4.5.1. 2,3,9-Trihydroxyl-10-methoxy-13-n-
nonylprotoberberine chloride (14)
To a stirred solution of 2 (1.0 g, 2.0 mmol) in CH2Cl2 (80 mL),
AlCl3 (1.18 g, 8.83 mmol) was added. The reaction mixture
was stirred at room temperature for 3 days. The solvent was
removed by evaporation and the residue was acidiﬁed with
4 M HCl, and then redissolved in MeOH. The solvent was
removed by evaporation and the residue was puriﬁed by ﬂash
chromatography over silica gel using CH2Cl2/CH3OH as the
gradient eluent, affording compound 14 (0.90 g, 95%) as a
dark red powder. Mp 110112 1C; 1H NMR (CD3OD) d 0.85
(t, J¼7.2 Hz, 3H), 1.241.31 (m, 10H), 1.421.44 (m, 2H),
1.811.82 (m, 2H), 2.96 (t, J¼5.6 Hz, 2H), 3.34 (t, J¼8.0 Hz,
2H), 4.03 (s, 3H), 4.67 (t, J¼5.6 Hz, 2H), 6.82 (s, 1H), 7.22 (s,
1H), 7.79, 7.97 (dd, J¼9.2 Hz, 2H), 9.70 ppm (s, 1H); 13C
NMR [(CD3)2SO] d 14.0, 22.1, 26.9, 28.6, 28.7, 28.9, 29.1,
30.3, 31.3 (2), 57.0, 57.1, 114.9, 115.6, 116.7, 117.1, 117.9,
124.7, 130.1, 131.9, 132.6, 135.6, 144.1, 144.2, 144.3, 144.8,
148.0 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C27H34NO4Cl: 436.2488, Found: 436.2498.
4.5.2. 2,3-Ethylenedioxy-9-hydroxyl-10-methoxy-13-n-
nonylprotoberberine chloride (15a)
To a stirred solution of 14 (150 mg, 0.42 mmol) and K2CO3
(175 mg, 1.27 mmol) in DMF (10 mL), 1,2-dibromoethane
(28.6 mL, 0.32 mmol) was added. The reaction mixture was
stirred at 70 1C for 56 h and then the solvent was removed
by evaporation. The residue was acidiﬁed with 2 M HCl and
the precipitate was collected by ﬁltration and puriﬁed by ﬂash
chromatography over silica gel using CH2Cl2/CH3OH (95/5)
as the gradient eluent, affording compound 15a (36 mg, 23%)
as a dark red powder. Mp 7981 1C; 1H NMR [(CD3)2SO] d
0.86 (t, J¼7.2 Hz, 3H), 1.061.25 (m, 10H), 1.431.44 (m,
2H), 1.79 (br, 2H), 3.02 (s, 2H), 3.25 (t, J¼8.8 Hz, 2H), 4.04
(s, 3H), 4.324.36 (m, 4H), 4.75 (s, 2H), 7.03 (s, 1H), 7.23 (s,
1H), 7.86, 8.08 (dd, J¼9.2 Hz, 2H), 9.89 (s, 1H), 11.27 ppm (s,
1H); 13C NMR [(CD3)2SO] d 13.8, 21.9, 26.7, 28.3, 28.5 (2),
28.7, 28.8, 30.1, 31.1, 56.9 (2), 64.0, 64.5, 115.7, 116.0, 117.1,
117.8, 119.9, 124.5, 131.4, 131.8, 133.4, 134.4, 141.9, 144.2,
144.6, 144.9, 145.0 ppm; HR MS-ESI: m/z [MCl]þ calcd. for
C29H36NO4Cl: 462.2644, Found: 462.2644.
4.5.3. 2-Hydroxyl-3,9-diethoxy-10-methoxy-13-n-
nonylprotoberberine chloride (15b)
This compound (15b) was obtained from ethyl bromide and
compound 14 as a brown powder (54 mg, 24%) using
Procedure C. Mp 7678 1C; 1H NMR (CD3OD) d 0.90 (t,
J¼6.8 Hz, 3H), 1.291.36 (m, 10H), 1.461.52 (m, 8H),
1.901.92 (m, 2H), 3.07 (t, J¼5.6 Hz, 2H), 3.44 (t, J¼6.4 Hz,
2H), 4.11 (s, 3H), 4.154.20 (m, 2H), 4.454.51 (m, 2H), 4.80
(t, J¼5.6 Hz, 2H), 6.94 (s, 1H), 7.36 (s, 1H), 8.13 (s, 2H),
9.71 ppm (s, 1H); 13C NMR [(CD3)2SO] d 13.9, 14.6, 14.7,
15.3, 22.0, 26.9, 28.5, 28.6, 28.8, 29.0, 30.8, 31.2, 56.9, 57.4,
63.9, 67.0, 112.0, 116.1, 119.0, 121.0, 121.5, 125.7, 130.2, 132.3,
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ESI: m/z [MCl]þ calcd. for C31H42NO4Cl: 492.3114, Found:
492.3146.
4.5.4. 2,3,9-Triethoxy-10-methoxy-13-n-nonylprotoberberine
chloride (15c)
This compound (15c) was obtained from ethyl bromide and
compound 14 as a brownish red powder (27 mg, 32%) using
Procedure C. Mp 8688 1C; 1H NMR (CD3OD) d 0.85 (t,
J¼7.0 Hz, 3H), 1.231.28 (m, 12H), 1.36 (t, J¼7.0 Hz, 3H),
1.39 (t, J¼7.0 Hz, 3H), 1.44 (t, J¼7.0 Hz, 3H), 1.81 (br, 2H),
3.08 (t, J¼6.0 Hz, 2H), 3.36 (s, 2H), 4.07 (s, 3H), 4.09 (q,
J¼5.6 Hz, 2H), 4.16 (q, J¼5.6 Hz, 2H), 4.36 (q, J¼5.6 Hz,
2H), 4.82 (s, 2H), 7.16 (s, 1H), 7.30 (s, 1H), 8.17 (s, 2H),
9.80 ppm (s, 1H); 13C NMR [(CD3)2SO] d 13.9, 14.6, 14.7,
15.3, 22.0, 26.9, 28.6, 28.8, 28.9, 29.1, 29.3, 30.8, 31.2, 56.9,
57.2, 64.0, 64.4, 67.0, 112.1, 114.6, 118.9, 121.0, 121.5, 125.8,
132.3 (2), 133.5, 135.8, 143.1, 144.3, 146.4, 150.1, 150.3 ppm;
HR MS-ESI: m/z [MCl]þ calcd. for C33H46NO4Cl: 520.3425,
Found: 520.3427.
4.6. Biological activity assay
All synthesized compounds were measured for their anti-TB
activities against the multiplication of drug-susceptible or
drug-resistant M. tuberculosis strains with MABA at different
concentration with RIF and INH as positive controls. Sub-
sequent two-fold dilutions were performed in 100 mL of 7H9
media in the 48-well microplates, and then 100 mL of bacterial
suspension was added to the wells. The amount of bacteria in
each well was 4 104 mg/mL. Plates were incubated at 37 1C.
At the optimal time, alamar blue solution was added to the
plate. Results were recorded at 24 h post-reagent addition.
Visual MIC was deﬁned as the lowest concentration of drug
that prevented a color change.
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